Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/434
Title: Targeted therapy in prostate cancer.
Epworth Authors: Corcoran, Niall
Other Authors: Gleave, M.
Keywords: Epworth Prostate Centre, Epworth HealthCare Richmond, Melbourne, Vic., Australia
Prostate Cancer
Prostate
Cancer
Neoplasms
Therapeutic Use
Male
Molecular Targeted Therapy
Drug Therapy
Pathology
Prostatic Neoplasms
Drug Effects
Tumor Invasion
Treatment Resistance
Targeted Therapy
Antineoplastic Agents
Issue Date: Jan-2012
Publisher: Wiley
Citation: Histopathology. 2012 Jan;60(1):216-31
Abstract: The therapeutic approach to advanced prostate cancer has seen greater changes in the last 7 years than it did in the preceding 70. Although only one of the newly approved agents that improve overall survival is a targeted agent, it is a validation of the method of pathway analysis and drug design in delivering novel, clinically usable agents. As our knowledge of the molecular circuitry of tumour invasion, metastases and treatment resistance has become more refined, the number of new, potentially useful, targets has grown exponentially. This is reflected in the vast array of diverse targeted agents that are currently being evaluated in human trials. In this review, we briefly describe some of the key pathways that are involved in the evolution of the prostate cancer 'lethal phenotype', and review the clinical activity of some of the newly approved targeted therapies or those in advanced phases of clinical development.
URI: http://hdl.handle.net/11434/434
DOI: 10.1111/j.1365-2559.2011.04030.x.
PubMed URL: http://www.ncbi.nlm.nih.gov/pubmed/22212088
ISSN: 1365-2559
Journal Title: Histopathology
Type: Journal Article
Affiliated Organisations: Department of Surgery, University of Melbourne, Royal Melbourne Hospital, Parkville, Victoria, Australia
Type of Clinical Study or Trial: Review
Appears in Collections:Cancer Services
Epworth Prostate Centre

Files in This Item:
There are no files associated with this item.


Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.